NASDAQ: AMRNAmarin Corp PLC Stock
$0.92+0.02 (+2.22%)
Updated Apr 17, 2024
AMRN Price
$0.92
Fair Value Price
$1.50
Market Cap
$376.59M
52 Week Low
$0.65
52 Week High
$1.49
P/E
-6.11x
P/B
0.68x
P/S
1.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$306.91M
Earnings
-$59.11M
Gross Margin
53.9%
Operating Margin
-17.48%
Profit Margin
-19.3%
Debt to Equity
0.51
Operating Cash Flow
$7M
Beta
1.19
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AMRN Overview
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Zen Score
–
Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMRN ($0.92) is undervalued by 38.71% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMRN ($0.92) is significantly undervalued by 38.71% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMRN due diligence checks available for Premium users.
Be the first to know about important AMRN news, forecast changes, insider trades & much more!
AMRN News
Valuation
AMRN fair value
Fair Value of AMRN stock based on Discounted Cash Flow (DCF)
Price
$0.92
Fair Value
$1.50
Undervalued by
38.51%
AMRN ($0.92) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMRN ($0.92) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.11x
Industry
153.9x
Market
41.64x
AMRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
5.79x
AMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMRN's financial health
Profit margin
Revenue
$74.7M
Net Income
-$5.8M
Profit Margin
-7.7%
AMRN's Earnings (EBIT) of -$53.66M... subscribe to Premium to read more.
Interest Coverage Financials
AMRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$831.7M
Liabilities
$279.6M
Debt to equity
0.51
AMRN's short-term assets ($724.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRN's short-term assets ($724.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$645.0k
Investing
-$71.0M
Financing
$83.0k
AMRN's operating cash flow ($6.88M)... subscribe to Premium to read more.
Debt Coverage Financials
AMRN vs General Drug Manufacturer Stocks
Amarin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.